tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Zenas BioPharma expects cash to fund operations into Q4 of 2026
PremiumThe FlyZenas BioPharma expects cash to fund operations into Q4 of 2026
12d ago
Sixteen new option listings on July 23rd
Premium
The Fly
Sixteen new option listings on July 23rd
1M ago
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
Premium
Ratings
Promising Future for Zenas BioPharma: Buy Rating Backed by Unique Product Advantage and Strong Pipeline Developments
1M ago
Zenas BioPharma Reports Q1 2025 Financial Results
PremiumCompany AnnouncementsZenas BioPharma Reports Q1 2025 Financial Results
3M ago
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
Premium
Ratings
Zenas BioPharma’s Promising Autoimmune Pipeline and Obexelimab’s Competitive Edge Drive Buy Rating
3M ago
Zenas BioPharma reports Q1 EPS (80c) vs ($17.89) last year
Premium
The Fly
Zenas BioPharma reports Q1 EPS (80c) vs ($17.89) last year
3M ago
Zenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO
PremiumThe FlyZenas BioPharma appoints Lisa von Moltke as Head of R&D, CMO
5M ago
Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target
Premium
Ratings
Zenas BioPharma’s Obexelimab: A Promising Therapy with a Buy Rating and $30 Price Target
5M ago
Zenas BioPharma announces objectives for 2025
Premium
The Fly
Zenas BioPharma announces objectives for 2025
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100